Part A of MOMENTUM is now complete and Sarepta will work with great urgency to discuss the results with regulatory agencies and gain their insights including the development path to support an accelerated approval of SRP5051 in the United States Results from the 30 mgkg dose cohort In biopsies taken at a median of week 12 30 mgkg of SRP5051 dosed monthly resulted in mean exon skipping of 1079 n4